Ensem Therapeutics, a Boston, MA-based biotechnology company, raised $67M in Series A funding.
The round was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, and CBC Group.
The company intends to use the funds to further advance its Kinetic Ensemble platform and accelerate R&D pipeline.
Led by Sean Cao, CEO, Ensembles Therapeutics is a drug discovery and development company that leverages its Kinetic Ensemble platform to develop innovative small molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas. ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets.
FinSMEs
08/04/2022